Navigation Links
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Date:10/28/2008

Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio

FAIRFIELD, N.J., Oct. 28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a licensing agreement with Perrigo Company (Nasdaq: PRGO) for the U.S. marketing rights to Centany(R) Ointment and two prescription keratolytic brands. Patented through 2018, Centany(R) represents an important step in Medimetriks' plan to commercialize patent-protected therapies for the Dermatology and Podiatry markets that offer important patient benefits. Medimetriks plans to launch Centany(R) in early 2009, with the two additional products following shortly thereafter.

Previously marketed by Johnson & Johnson's OrthoNeutrogena professional division, Centany(R) is indicated for the topical treatment of impetigo due to Straphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. Centany(R) received a New Drug Approval in December of 2002 based in part on the unique properties of its vehicle, which offers important benefits over its competitors.

The two prescription keratolytic brands are urea-based therapies indicated for the treatment of severe dry skin. They are offered in delivery systems that are gaining wide acceptance in the Dermatology and Podiatry markets and are both patent pending. These new brands will compete in a skin softening market that approaches one million prescriptions annually.

"We are happy to have a partner that brings such a record of success in the branded pharmaceutical business," stated Sharon Kochan, Executive Vice President of Perrigo. "We believe the licensed products are in good hands given Medimetriks management's proven abilities in building a successful business in the Dermatology and Podiatry markets."

Medimetriks President and CEO, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio. Perrigo is known for developing high quality products and we believe these brands will benefit both our core Dermatology and Podiatry audiences and their patients."

Centany(R) is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of Centany(R): application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Please see full prescribing information.

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at http://www.medimetriks.com, call (973) 882-7512 or fax (973) 882-7502.


'/>"/>
SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
2. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
3. Perrigo Company Announces Appointment of New Board Member
4. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
5. Perrigo Announces Approval for Rx Cetirizine Syrup
6. Perrigo Confirms Filing for Generic Version of VANOS(R)
7. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
8. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
9. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
10. Perrigo Company Announces Quarterly Dividend
11. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
Breaking Medicine Technology: